RT Journal Article
T1 Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party.
A1 Penack, Olaf
A1 Peczynski, Christophe
A1 van-der-Werf, Steffie
A1 Finke, Jürgen
A1 Ganser, Arnold
A1 Schoemans, Helene
A1 Pavlu, Jiri
A1 Niittyvuopio, Riitta
A1 Schroyens, Wilfried
A1 Kaynar, Leylagül
A1 Blau, Igor W
A1 van-der-Velden, Walter
A1 Sierra, Jorge
A1 Cortelezzi, Agostino
A1 Wulf, Gerald
A1 Turlure, Pascal
A1 Rovira, Montserat
A1 Ozkurt, Zubeydenur
A1 Pascual-Cascon, Maria J
A1 Moreira, Maria C
A1 Clausen, Johannes
A1 Greinix, Hildegard
A1 Duarte, Rafael F
A1 Basak, Grzegorz W
K1 Myelodysplastic Syndromes
K1 Inflammation
K1 Leukemia
K1 Lymphoma
AB Uric acid is a danger signal contributing to inflammation. Its relevance to allogeneic stem cell transplantation (alloSCT) derives from preclinical models where the depletion of uric acid led to improved survival and reduced graft-versus-host disease (GvHD). In a clinical pilot trial, peri-transplant uric acid depletion reduced acute GvHD incidence. This prospective international multicenter study aimed to investigate the association of uric acid serum levels before start of conditioning with alloSCT outcome. We included patients with acute leukemia, lymphoma or myelodysplastic syndrome receiving a first matched sibling alloSCT from peripheral blood, regardless of conditioning. We compared outcomes between patients with high and low uric acid levels with univariate- and multivariate analysis using a cause-specific Cox model. Twenty centers from 10 countries reported data on 366 alloSCT recipients. There were no significant differences in terms of baseline comorbidity and disease stage between the high- and low uric acid group. Patients with uric acid levels above median measured before start of conditioning did not significantly differ from the remaining in terms of acute GvHD grades II-IV incidence (Hazard ratio [HR] 1.5, 95% Confidence interval [CI]: 1.0-2.4, P=0.08). However, they had significantly shorter overall survival (HR 2.8, 95% CI: 1.7-4.7, P<0.0001) and progression free survival (HR 1.6, 95% CI: 1.1-2.4, P=0.025). Non-relapse mortality was significantly increased in alloSCT recipients with high uric acid levels (HR 2.7, 95% CI: 1.4-5.0, P=0.003). Finally, the incidence of relapse after alloSCT was increased in patients with higher uric acid levels (HR 1.6, 95% CI: 1.0-2.5, P=0.04). We conclude that high uric acid levels before the start of conditioning correlate with increased mortality after alloSCT.
PB Fondazione Ferrata Storti
YR 2019
FD 2019-10-10
LK http://hdl.handle.net/10668/15499
UL http://hdl.handle.net/10668/15499
LA en
NO Penack O, Peczynski C, van der Werf S, Finke J, Ganser A, Schoemans H, et al. Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party. Haematologica. 2020 Jul;105(7):1977-1983
DS RISalud
RD Apr 17, 2025